Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Core Viewpoint - Coherus BioSciences, Inc. is set to release its fourth quarter and full year 2024 financial results on March 10, 2025, followed by a conference call to discuss these results and provide a business update [1]. Financial Results Announcement - The financial results will be released after market close on March 10, 2025 [1]. - A conference call and webcast will begin at 5:00 p.m. ET on the same day [2]. Conference Call Details - Participants must pre-register to receive dial-in information and a personal PIN for the live call [2]. - A live and archived webcast will be available on the Coherus website after the conference call [3]. - Attendees are advised to dial in 15 minutes early for a timely connection [3]. Company Overview - Coherus is a commercial-stage biopharmaceutical company focused on innovative immunotherapies for cancer treatment [5]. - The company markets LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, and is developing a robust immuno-oncology pipeline [5]. Immuno-Oncology Pipeline - Coherus' pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors [6]. - Casdozokitug, an IL-27 antagonistic antibody, is currently in three clinical studies, including a Phase 1/2 study for advanced solid tumors [6]. - CHS-114, a selective anti-CCR8 antibody, is in a Phase 1 study for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC) [6].